Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $123 from $113 and keeps an Overweight rating on the shares after the company delivered a Q4 beat and gave 2025 EPS guidance that was ahead of consensus. The firm sees potential for upward estimate revisions and further multiple expansion as the company progresses its next-gen HIV pipeline, the analyst tells investors in an earnings recap.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $100 from $95 at Baird
- Gilead price target raised to $110 from $105 at Piper Sandler
- Gilead price target raised to $120 from $105 at Wells Fargo
- Gilead Sciences: Balancing Strong HIV Franchise Performance with Cautious Outlook
- Gilead Sciences Reports Strong 2024 Financial Performance